| Dr Mary E Young, MD | |
|
2002 Medical Pkwy, Suite 235, Annapolis, MD 21401-3046 | |
| (410) 266-2770 | |
| (410) 841-6251 |
| Full Name | Dr Mary E Young |
|---|---|
| Gender | Female |
| Speciality | Radiation Oncology |
| Experience | 42 Years |
| Location | 2002 Medical Pkwy, Annapolis, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619979366 | NPI | - | NPPES |
| 2622593 | Other | MD | AETNA HMO/POS |
| 10690004 | Other | MD | BCBS |
| 8317071 | Other | MD | AETNA PPO |
| Facility Name | Location | Facility Type |
|---|---|---|
| Anne Arundel Medical Center | Annapolis, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Brown, Croft, Frazier, Pa | 9537101746 | 24 |
News Archive
Envision will hold its 10th annual Assistive Technology (AT) Camps May 26 to 31 (for middle school students) and June 26 – July 2 (for high school students). The weeklong programs are designed to establish independence through college and career development as well as provide technology instruction for children and teens who are blind or visually impaired.
The gene p53 is the most commonly mutated gene in cancer - it is p53's job to monitor cells for DNA damage and to mark damaged cells for destruction and so cancer cells with mutated DNA must disable p53 before it disables them.
The Academy of Nutrition and Dietetics has created a unique web application platform with tools to help registered dietitian nutritionists provide the highest-quality care for patients and clients, track outcomes of their interventions, conduct research in important areas of nutrition science and contribute to a national quality registry.
Scientists used fruit flies to show for the first time that a new class of genetically engineered proteins can be used to watch nerve cell electrical activity in live brains. The results, published in Cell, suggest these proteins may be a promising new tool for mapping brain cell activity in multiple animals and for studying how neurological disorders disrupt normal nerve cell signaling.
InNexus Biotechnology Inc. has announced the United States Food & Drug Administration (FDA) has completed its comprehensive review of the development plans for InNexus' lead preclinical candidate, DXL625 (CD20) for the prospective treatment of Non-Hodgkin's Lymphoma (NHL) and/or Chronic Lymphocytic Leukemia (CLL).
› Verified 6 days ago
| Entity Name | Brown, Croft, Frazier, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902807324 PECOS PAC ID: 9537101746 Enrollment ID: O20050527000410 |
News Archive
Envision will hold its 10th annual Assistive Technology (AT) Camps May 26 to 31 (for middle school students) and June 26 – July 2 (for high school students). The weeklong programs are designed to establish independence through college and career development as well as provide technology instruction for children and teens who are blind or visually impaired.
The gene p53 is the most commonly mutated gene in cancer - it is p53's job to monitor cells for DNA damage and to mark damaged cells for destruction and so cancer cells with mutated DNA must disable p53 before it disables them.
The Academy of Nutrition and Dietetics has created a unique web application platform with tools to help registered dietitian nutritionists provide the highest-quality care for patients and clients, track outcomes of their interventions, conduct research in important areas of nutrition science and contribute to a national quality registry.
Scientists used fruit flies to show for the first time that a new class of genetically engineered proteins can be used to watch nerve cell electrical activity in live brains. The results, published in Cell, suggest these proteins may be a promising new tool for mapping brain cell activity in multiple animals and for studying how neurological disorders disrupt normal nerve cell signaling.
InNexus Biotechnology Inc. has announced the United States Food & Drug Administration (FDA) has completed its comprehensive review of the development plans for InNexus' lead preclinical candidate, DXL625 (CD20) for the prospective treatment of Non-Hodgkin's Lymphoma (NHL) and/or Chronic Lymphocytic Leukemia (CLL).
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mary E Young, MD 2002 Medical Pkwy, Suite 235, Annapolis, MD 21401-3046 Ph: (410) 266-2770 | Dr Mary E Young, MD 2002 Medical Pkwy, Suite 235, Annapolis, MD 21401-3046 Ph: (410) 266-2770 |
News Archive
Envision will hold its 10th annual Assistive Technology (AT) Camps May 26 to 31 (for middle school students) and June 26 – July 2 (for high school students). The weeklong programs are designed to establish independence through college and career development as well as provide technology instruction for children and teens who are blind or visually impaired.
The gene p53 is the most commonly mutated gene in cancer - it is p53's job to monitor cells for DNA damage and to mark damaged cells for destruction and so cancer cells with mutated DNA must disable p53 before it disables them.
The Academy of Nutrition and Dietetics has created a unique web application platform with tools to help registered dietitian nutritionists provide the highest-quality care for patients and clients, track outcomes of their interventions, conduct research in important areas of nutrition science and contribute to a national quality registry.
Scientists used fruit flies to show for the first time that a new class of genetically engineered proteins can be used to watch nerve cell electrical activity in live brains. The results, published in Cell, suggest these proteins may be a promising new tool for mapping brain cell activity in multiple animals and for studying how neurological disorders disrupt normal nerve cell signaling.
InNexus Biotechnology Inc. has announced the United States Food & Drug Administration (FDA) has completed its comprehensive review of the development plans for InNexus' lead preclinical candidate, DXL625 (CD20) for the prospective treatment of Non-Hodgkin's Lymphoma (NHL) and/or Chronic Lymphocytic Leukemia (CLL).
› Verified 6 days ago
Luqman K Dad, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 2002 Medical Pkwy, Suite 235, Annapolis, MD 21401 Phone: 410-266-2770 Fax: 410-841-6251 | |
Dr. Quang Nguyen, Radiology Medicare: Accepting Medicare Assignments Practice Location: 2001 Medical Pkwy, Annapolis, MD 21401 Phone: 410-266-2770 Fax: 410-841-6251 | |
Dr. Mark S Radowich, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 2002 Medical Pkwy, Suite 235, Annapolis, MD 21401 Phone: 410-266-2770 Fax: 410-841-6251 | |
Dr. Thomas B. Lank, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 122 Defense Hwy, Chesapeake Medical Imaging, Annapolis, MD 21401 Phone: 410-571-0350 Fax: 410-571-9348 | |
Dr. Frank J Groshek, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 2002 Medical Pkwy Ste 235, Annapolis, MD 21401 Phone: 410-266-2770 Fax: 410-841-6251 | |
Dr. Mark Cameron Davis, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 845 Coachway, Annapolis, MD 21401 Phone: 952-595-1100 Fax: 612-294-4903 | |
Dr. Kerry J. Thompson, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 2002 Medical Pkwy, Suite #235, Annapolis, MD 21401 Phone: 410-266-2770 Fax: 410-841-6251 |